Neumora Therapeutics, Inc. Asset Resilience Ratio
Neumora Therapeutics, Inc. asset resilience ratio. Neumora Therapeutics, Inc. (NMRA) has an Asset Resilience Ratio of 23.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Neumora Therapeutics, Inc. defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Neumora Therapeutics, Inc. (2021–2024)
Asset resilience ratio of Neumora Therapeutics, Inc. from 2021 to 2024. This chart shows how Neumora Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Read how much debt does Neumora Therapeutics, Inc. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Neumora Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see NMRA current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $42.45 Million | 23.87% |
| Total Liquid Assets | $42.45 Million | 23.87% |
Asset Resilience Insights
- Good Liquidity Position: Neumora Therapeutics, Inc. maintains a healthy 23.87% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Neumora Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Neumora Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Neumora Therapeutics, Inc. Asset Resilience Ratio by Year (2021–2024)
Neumora Therapeutics, Inc. asset resilience ratio by year from 2021 to 2024. The table below shows the annual Asset Resilience Ratio data for Neumora Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.19% | $165.43 Million | $316.97 Million | +36.08pp |
| 2023-12-31 | 16.11% | $79.94 Million | $496.19 Million | -14.61pp |
| 2022-12-31 | 30.72% | $130.94 Million | $426.23 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $429.30 Million | -- |
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive diso… Read more